These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

125 related items for PubMed ID: 17134848

  • 1. Angiotensin II, corticosteroids, type II diabetes and the metabolic syndrome.
    Vinson GP.
    Med Hypotheses; 2007; 68(6):1200-7. PubMed ID: 17134848
    [Abstract] [Full Text] [Related]

  • 2. Of the renin-angiotensin system and reactive oxygen species Type 2 diabetes and angiotensin II inhibition.
    Leiter LA, Lewanczuk RZ.
    Am J Hypertens; 2005 Jan; 18(1):121-8. PubMed ID: 15691626
    [Abstract] [Full Text] [Related]

  • 3. Pancreatic renin-angiotensin-aldosterone system in the cardiometabolic syndrome and type 2 diabetes mellitus.
    Hayden MR, Sowers JR.
    J Cardiometab Syndr; 2008 Jan; 3(3):129-31. PubMed ID: 18983326
    [No Abstract] [Full Text] [Related]

  • 4. Role of renin-angiotensin system in adipose tissue dysfunction.
    Iwai M, Horiuchi M.
    Hypertens Res; 2009 Jun; 32(6):425-7. PubMed ID: 19407825
    [Abstract] [Full Text] [Related]

  • 5. Local renin-angiotensin systems and their interactions with extra-adrenal corticosteroid production.
    MacKenzie SM, Fraser R, Connell JM, Davies E.
    J Renin Angiotensin Aldosterone Syst; 2002 Dec; 3(4):214-21. PubMed ID: 12584665
    [Abstract] [Full Text] [Related]

  • 6. The metabolic syndrome: metabolic changes with vascular consequences.
    Wassink AM, Olijhoek JK, Visseren FL.
    Eur J Clin Invest; 2007 Jan; 37(1):8-17. PubMed ID: 17181562
    [Abstract] [Full Text] [Related]

  • 7. Angiotensin II and the development of insulin resistance: implications for diabetes.
    Olivares-Reyes JA, Arellano-Plancarte A, Castillo-Hernandez JR.
    Mol Cell Endocrinol; 2009 Apr 29; 302(2):128-39. PubMed ID: 19150387
    [Abstract] [Full Text] [Related]

  • 8. Mechanisms of protective effects induced by blockade of the renin-angiotensin system: novel role of the pancreatic islet angiotensin-generating system in Type 2 diabetes.
    Leung PS.
    Diabet Med; 2007 Feb 29; 24(2):110-6. PubMed ID: 17257271
    [Abstract] [Full Text] [Related]

  • 9. Renin-angiotensin system, natriuretic peptides, obesity, metabolic syndrome, and hypertension: an integrated view in humans.
    Sarzani R, Salvi F, Dessì-Fulgheri P, Rappelli A.
    J Hypertens; 2008 May 29; 26(5):831-43. PubMed ID: 18398321
    [Abstract] [Full Text] [Related]

  • 10. Spotlight on renin. The renin system, salt-sensitivity and metabolic syndrome.
    Fujita T.
    J Renin Angiotensin Aldosterone Syst; 2006 Sep 29; 7(3):181-3. PubMed ID: 17094057
    [No Abstract] [Full Text] [Related]

  • 11. Protection of pancreatic beta-cells: is it feasible?
    Bonora E.
    Nutr Metab Cardiovasc Dis; 2008 Jan 29; 18(1):74-83. PubMed ID: 18096375
    [Abstract] [Full Text] [Related]

  • 12. The renin-angiotensin-aldosterone system: a pivotal role in insulin sensitivity and glycemic control.
    Perkins JM, Davis SN.
    Curr Opin Endocrinol Diabetes Obes; 2008 Apr 29; 15(2):147-52. PubMed ID: 18316950
    [Abstract] [Full Text] [Related]

  • 13. Cross talk of tumor necrosis factor-alpha and the renin-angiotensin system in tumor necrosis factor-alpha-induced plasminogen activator inhibitor-1 production from hepatocytes.
    Takeshita Y, Takamura T, Ando H, Hamaguchi E, Takazakura A, Matsuzawa-Nagata N, Kaneko S.
    Eur J Pharmacol; 2008 Jan 28; 579(1-3):426-32. PubMed ID: 18078928
    [Abstract] [Full Text] [Related]

  • 14. The intracellular renin-angiotensin system: a new paradigm.
    Kumar R, Singh VP, Baker KM.
    Trends Endocrinol Metab; 2007 Jul 28; 18(5):208-14. PubMed ID: 17509892
    [Abstract] [Full Text] [Related]

  • 15. Metabolic stress in insulin's target cells leads to ROS accumulation - a hypothetical common pathway causing insulin resistance.
    Eriksson JW.
    FEBS Lett; 2007 Jul 31; 581(19):3734-42. PubMed ID: 17628546
    [Abstract] [Full Text] [Related]

  • 16. Metabolic syndrome: psychosocial, neuroendocrine, and classical risk factors in type 2 diabetes.
    Abraham NG, Brunner EJ, Eriksson JW, Robertson RP.
    Ann N Y Acad Sci; 2007 Oct 31; 1113():256-75. PubMed ID: 17513461
    [Abstract] [Full Text] [Related]

  • 17. The role of the renin-angiotensin system in the pathophysiology, prevention, and treatment of renal impairment in patients with the cardiometabolic syndrome or its components.
    Alpert MA, Govindarajan G, Del Rosario ML, Reisin E.
    J Cardiometab Syndr; 2009 Oct 31; 4(1):57-62. PubMed ID: 19245518
    [Abstract] [Full Text] [Related]

  • 18. Increased insulin-stimulated expression of arterial angiotensinogen and angiotensin type 1 receptor in patients with type 2 diabetes mellitus and atheroma.
    Hodroj W, Legedz L, Foudi N, Cerutti C, Bourdillon MC, Feugier P, Beylot M, Randon J, Bricca G.
    Arterioscler Thromb Vasc Biol; 2007 Mar 31; 27(3):525-31. PubMed ID: 17170378
    [Abstract] [Full Text] [Related]

  • 19. Effects of insulin resistance on endothelial progenitor cells and vascular repair.
    Cubbon RM, Kahn MB, Wheatcroft SB.
    Clin Sci (Lond); 2009 Aug 03; 117(5):173-90. PubMed ID: 19630751
    [Abstract] [Full Text] [Related]

  • 20. From mitochondria to disease: role of the renin-angiotensin system.
    de Cavanagh EM, Inserra F, Ferder M, Ferder L.
    Am J Nephrol; 2007 Aug 03; 27(6):545-53. PubMed ID: 17785964
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.